Lotus Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Lotus Pharmaceutical wird ein Gewinn- und Umsatzwachstum von 25.5% bzw. 13.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 25.7% pro Jahr wachsen soll.

Wichtige Informationen

25.5%

Wachstumsrate der Gewinne

25.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	41.8%
Wachstumsrate der Einnahmen	13.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19

Gewinn- und Umsatzwachstumsprognosen

TWSE:1795 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	20,954	6,170	5,005	7,123	3
12/31/2024	18,861	4,825	4,260	4,964	5
3/31/2024	16,632	3,948	1,717	3,325	N/A
12/31/2023	16,958	4,106	-1,661	1,614	N/A
9/30/2023	16,710	3,873	-918	3,440	N/A
6/30/2023	17,527	4,707	-1,211	2,974	N/A
3/31/2023	15,995	3,769	-894	3,251	N/A
12/31/2022	14,633	3,021	650	3,719	N/A
9/30/2022	14,264	3,105	181	2,198	N/A
6/30/2022	11,932	1,374	-227	2,012	N/A
3/31/2022	12,486	1,401	-1,892	496	N/A
12/31/2021	12,649	1,403	-1,496	120	N/A
9/30/2021	12,977	1,470	-1,029	421	N/A
6/30/2021	12,806	1,400	-1,182	26	N/A
3/31/2021	12,019	1,344	371	1,447	N/A
12/31/2020	10,729	1,027	-49	1,949	N/A
9/30/2020	10,802	848	-552	1,619	N/A
6/30/2020	9,933	769	-863	1,116	N/A
3/31/2020	9,307	519	-980	905	N/A
12/31/2019	9,611	663	-686	420	N/A
9/30/2019	8,130	596	-523	266	N/A
6/30/2019	7,693	463	1	691	N/A
3/31/2019	7,278	359	39	720	N/A
12/31/2018	6,429	99	403	797	N/A
9/30/2018	6,537	38	401	774	N/A
6/30/2018	6,535	19	277	657	N/A
3/31/2018	6,477	110	-274	623	N/A
12/31/2017	6,424	22	N/A	591	N/A
9/30/2017	6,072	-171	N/A	696	N/A
6/30/2017	5,897	-252	N/A	965	N/A
3/31/2017	5,913	-270	N/A	1,186	N/A
12/31/2016	5,903	-134	N/A	1,233	N/A
9/30/2016	5,896	78	N/A	1,490	N/A
6/30/2016	5,910	126	N/A	1,378	N/A
3/31/2016	5,653	198	N/A	1,223	N/A
12/31/2015	5,522	104	N/A	1,078	N/A
9/30/2015	4,712	-102	N/A	436	N/A
6/30/2015	3,879	-204	N/A	-531	N/A
3/31/2015	3,125	-312	N/A	-886	N/A
12/31/2014	2,310	-442	N/A	-1,032	N/A
9/30/2014	2,201	-307	N/A	-1,310	N/A
6/30/2014	2,152	-269	N/A	-503	N/A
3/31/2014	2,411	-330	N/A	-379	N/A
12/31/2013	2,092	-143	N/A	-388	N/A
9/30/2013	1,673	-178	N/A	72	N/A
6/30/2013	1,288	-126	N/A	-66	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1795Das prognostizierte Gewinnwachstum (25.5% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: 1795Die Erträge des Unternehmens (25.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (18% pro Jahr).

Hohe Wachstumserträge: 1795Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 1795Die Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (10.7% pro Jahr).

Hohe Wachstumseinnahmen: 1795Die Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1795 in 3 Jahren voraussichtlich hoch sein wird

Lotus Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 17% to NT$390

Price target increased by 7.3% to NT$301

Price target increased by 7.5% to NT$300

Price target increased to NT$235

Consensus EPS estimates increase by 25%

Price target increased to NT$179

Recent updates

Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. (TWSE:1795) agreed to acquire Teva Pharma (Thailand) Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.

First quarter 2024 earnings: EPS misses analyst expectations

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Price target increased by 17% to NT$390

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Full year 2023 earnings: EPS exceeds analyst expectations

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Jun 13, 2024

Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024

Lotus Pharmaceutical Co., Ltd. Reaches Settlement Agreement with Novartis for Midostaurin Capsules in the USA

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Lotus Pharmaceutical Co., Ltd. Announces Director Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson

Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members

Upcoming dividend of NT$3.46 per share at 1.0% yield

Lotus Pharmaceutical Co., Ltd. Announces Board Changes

Investor sentiment improves as stock rises 25%

Price target increased by 7.3% to NT$301

Price target increased by 7.5% to NT$300

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Investor sentiment improves as stock rises 15%

Lotus Pharmaceutical Co., Ltd. Receives Tentative Approval for Its ANDA for Nintedanib Capsules, 100 Mg and 150 Mg, from the US FDA

Investor sentiment improved over the past week

Lotus Pharmaceutical Co., Ltd. Announces Executive Changes

Price target increased to NT$235

Consensus EPS estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lotus Pharmaceutical Co., Ltd. Receives the Final Approval for Its ANDA for Lenalidomide Capsules, 5 Mg, 10 Mg, 15 Mg and 25 Mg from the US FDA

Lotus Pharmaceutical Co., Ltd. Receives Tentative Approval for Midostaur in ANDA from the US FDA

Investor sentiment improved over the past week

Price target increased to NT$179

Price target increased to NT$173

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of NT$1.93 per share

Lotus Pharmaceutical Co., Ltd. Declares Cash Dividend, Payable on August 31, 2021

Lotus Pharmaceutical Co., Ltd. Announces Election of Directors

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to NT$162

Less than half of directors are independent

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Lotus Pharmaceutical Co., Ltd. Announces Resignation of Hirofumi Imai as Director, Effective June 30, 2022

Investor sentiment improved over the past week

Consensus forecasts updated

Price target increased to NT$144

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$1.34 (vs NT$1.15 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS NT$1.38 (vs NT$1.23 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of NT$0.35 per share

Price target increased to NT$125

Price target increased to NT$112

First quarter 2021 earnings released: EPS NT$1.85 (vs NT$0.54 in 1Q 2020)

Consensus EPS estimates increase to NT$6.12

Director has left the company

Lotus Pharmaceutical Co., Ltd. announced that it expects to receive TWD 1.413649984 billion in funding from Innobic (Asia) Company Limited

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Full year 2020 earnings released: EPS NT$4.22 (vs NT$2.74 in FY 2019)

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?